Proposed membership of the Guideline Development Group (GDG) for the 2019 WHO Recommendations on preferred first-line and second-line antiretroviral regimens for treating HIV .

June 5-7, 2019.

Geneva, Switzerland

Elaine Abrams is an internationally recognized expert and clinician and has over 30 years of experience in comprehensive care and treatment for HIV-infected pregnant women, children and their families. As the senior director for research at ICAP, she leads ICAP’s large research agenda and is responsible for development and implementation of technical assistance, drug access, pediatric and perinatal prevention initiatives for ICAP programs in sub-Saharan Africa and Asia. She was the director of the MTCT-Plus Initiative, the first multi-country family-focused HIV treatment program that demonstrated successful provision of HIV care and antiretroviral treatment for pregnant women and their families in resource-limited settings. Dr. Abrams served three consecutive terms as Chair of the IMPAACT HIV treatment scientific committee and currently guides the IMPAACT network scientific agenda as a member of the Senior Leadership Group. She served as the co-chair of the guidelines group for WHO consolidated guidelines for the use of antiretroviral drugs in 2015 and 2018, introducing universal treatment, antiretrovirals for prevention and optimized ARV regimens with dolutegravir. She is also co-chair of the WHO Pediatric Antiretroviral Working Group (PAWG) and is actively involved in the development of international, national and local guidelines and policies for HIV care and treatment. Dr. Abrams’ research interests have focused on maternal health, mother-to-child HIV transmission, the natural history of pediatric HIV, and optimizing antiretroviral for infants, children, adolescents and pregnant women and breastfeeding women. Dr. Abrams is a professor of epidemiology and at Columbia University and holds a from Columbia University’s College of and .

Florence Anam is the HIV/TB Advocacy Coordinator -Africa at MSF (Doctors without borders) and based in South Africa. She has a Bachelor of Business Administration (BBA) degree from Maseno University and is currently pursuing a Master of Arts in Communication Studies at The University of Nairobi (UON). She has ten years’ experience actively working in HIV and AIDS programs in Kenya, regionally and globally. Florence is a seasoned advocate with years of community engagement in national regional and international advocacy representing WLHIV and their communities on issues such as Community engagement, access to treatment, maternal health, sexual and reproductive health rights, equality, and social justice and expanded economic and education access for women and girls.

Linda Barlow-Mosha is a Pediatrician and Senior Investigator at Makerere University-Johns Hopkins University Research Collaboration (MUJHU) in Kampala, Uganda with over 15 years of experience. She heads the HIV pediatric, adolescent and youth research domain. Dr Barlow-Mosha leads a varied portfolio of research that addresses critical scientific questions in pediatric HIV care and treatment as well as birth defects surveillance. She is the Senior Program manager of the Birth Defect Surveillance Project in Uganda. She has been involved in development of international and national guidelines for HIV prevention, care, and treatment and is a member of the IMPAACT HIV Scientific Treatment Committee. Her clinical and research interests are in complications of pediatric HIV infection, antiretroviral drug resistance and pharmacokinetics, birth defects, and learning disabilities. Dr Barlow- Mosha received her training from Johns Hopkins University (BA, and MPH), Howard University (MD), and Thomas Jefferson University (Pediatrics).

David Burger is a clinical pharmacology researcher and received his Degree at the Utrecht University in the Netherlands in 1990 and completed his PhD thesis in 1994. After this, he moved to the Radboud University Medical Centre, Nijmegen, for his hospital pharmacist training. Since 1997 he has been leading a research group focussing on clinical pharmacology of antimicrobial agents with emphasis on HIV, TB, fungal , and Hepatitis. He is a member of the Editorial Board of the www.hiv- druginteractions.org and www.hep-druginteractions.org websites. He is an Executive Editor of BJCP and serves on the editorial boards of TDM, JAIDS, JAC, Antiviral Therapy. Since April 2011 he has been appointed as a Professor of Clinical Pharmacy at the Radboud University Nijmegen. He is (co-) author of more than 450 publications in this field and has supervised >25 completed PhD theses. The topics of his interest are drug-drug interactions, paediatric pharmacology, therapeutic drug monitoring, and operational research in resource-limited countries.

Pedro Cahn is Professor of Infectious Diseases at the Buenos Aires University . Dr. Khan has been working on infectious diseases for the last 40 years and has been involved in the HIV/AIDS arena since 1982. He has served as Chief of Infectious Diseases at the Juan Fernandez Hospital in Buenos Aires, Argentina, where he is now Senior Consultant. He is Scientific Director at Fundación Huésped, the largest NGO in Argentina serving patients with and at risk of HIV/AIDS. Dr. Cahn´s team has contributed to identify new treatment strategies, promoting research on dual therapy. He also is Co-Chair of CCASANET, the Caribbean, Central and South America network, a cohort part of IeDEA and investigator with the IMPAACT network. He is also a Past-President of the International AIDS Society. He has served as external advisor for UNAIDS, the World Health Organization (WHO), the Pan-American Health Organization (PAHO), UNITAID and Doctors without Borders. He is as a member of the WHO antiretroviral guidelines panel, Chair of the Treatment Advisory Group at PAHO and a former member of the guidelines panel of the International Antiviral Society-USA. He is part of the Technical Advisory Committee on HIV at the National AIDS Program in Argentina. He has served as external advisor for the ARV guidelines panel in Mexico, South Africa and Uruguay. Dr. Cahn has published more than 200 peer- reviewed papers and book chapters.

Alexandra Calmy is a medical doctor, trained in internal and in Infectious diseases (FMH), and holds a PhD in clinical research PhD in HIV/AIDS obtained in Sydney, Australia. She is currently an associate Professor and head of the HIV/AIDS Unit in Geneva University Hospital. Dr. Calmy’s research interest is in the and humanitarian response to HIV/AIDS, specifically the provision of antiretroviral therapy and management of side-effects in resource limited settings. She has worked as a medical doctor with Medecins Sans Frontieres in Cambodia in 1996 and has subsequently supported MSF’s HIV/AIDS work for more than 10 years. She is a member of WHO working groups on the writing and the implementation of guidelines related to the treatment of HIV in developing countries since 2001, head of CSS13 committee at the Agence National de Recherche sur le SIDA (ANRS), member of the scientific board of the Swiss HIV Study Cohort (SHCS), and the Federal commission of Sexual Health in Switzerland. She is also a reviewer for numerous well recognized medical journals and has published over 200 articles in peer-reviewed medical journals.

Mohamed Chakroun is a medical doctor, specialist in infectious diseases, full time work in the Fattouma Bourgiba Teaching Hospital and Professor in the Faculty of Medicine, teaching infectious diseases and anti-infective agents in Tunisia. He’s providing care and supporting people living with HIV (PLHIV)with an extensive experience in HIV care, antiretroviral therapy (ART) and prevention. He has a history of engagement with national AIDS programme (NAP), community groups and health organizations in HIV care, prevention and policy development. He’s also national and regional expert on HIV/AIDS. He was scientific coordinator of the Tunisian Guidelines for Antiretroviral Therapy on 2010 then 2013. He provided several training on HIV testing counseling, ART, Management of opportunistic infections, and PMTCT in some countries(Djibouti, Egypt, Libya, Tunisia). He supported technically HIV/AIDS & STIs & Hepatitis (HAS)Unit in WHO Regional Office (Cairo, Egypt). He has authored many national and regional manuals on HIV/AIDS as well as several papers on HIV/AIDS in peer reviewed journals. He attended several WHO regional workshop and WHO intercountry meeting of NAP manager as temporary advisor. He was member of external review group for WHO consolidated guidelines for key populations (2014), HIV testing services (2015) and HIV self-testing (2016). He was also member of WHO Guideline Development Group for HIV post-exposure prophylaxis (2014) and the use of antiretroviral drugs (2016). Currently, he’s a member of the Global Network of Researchers on HIV/AIDS in the Middle East and the HIV Drug Resistance network.

Martin Choo is an AIDS activist based in Kuala Lumpur, Malaysia. He works as the General Manager of the Kuala Lumpur AIDS Support Services Society (KLASS), overseeing the implementation and skills building of community-based prevention and care services for people living with HIV. He is also a community-based researcher affiliated with the Asia Pacific Network of People Living with HIV (APN+). Martin has designed, implemented, analyzed and reported on peer-led participatory research among people living with HIV, men who have sex with men and transgender women. Martin was a member of the 2015WHOClinical and Consolidated Guidelines Development Groups on the use of antiretroviral drugs for treating and preventing HIV infection, as well as on HIV testing services. Since 2016, he has been a Trustee of the Asia Pacific Council of AIDS Service Organizations (APCASO). He has been living with HIV since 2004.

Mark Fredric Cotton is the Head of the Division of Pediatric Infectious Diseases and the Director of the Children's Infectious Diseases Clinical Research Unit at Tygerberg Children’s Hospital, Stellenbosch University, in South Africa. Dr. Cotton studied medicine at the University of Cape Town, where he received his Bachelor of Medicine and , and at the University of Witwatersrand, where he graduated with a in pediatrics. There, he also received a diploma in and health. Dr. Cotton received a post-doctoral scholarship at the Medical Research Council of South Africa in 1991 and went on to serve a in pediatric infectious diseases at the University of Colorado School of Medicine in Denver. In 2004, Dr Cotton earned his PhD from Stellenbosch University, where his dissertation focused on the role of apoptosis in pediatric HIV infection. Dr. Cotton has worked with the International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Network and the Pediatric European Network for Treatment of AIDS (PENTA). He has also partnered with the World Health Organization on HIV and TB initiatives. Dr Cotton has served as principal and co-principal investigator in several pediatric clinical trials, including on antiretroviral strategy (CHER), isoniazid prophylaxis, and ARV pharmacokinetics in HIV-infected children. He is the principal investigator for the SU Clinical Unit focusing on TB and HIV. In 1995 he received the Pediatric AIDS Foundation Scholar’s Award.

Serge Paul Eholie, MD, Senior Lecturer Unit of Infectious and Tropical Diseases Abidjan, Côte d’Ivoire. Professor Serge Paul Eholié is a professor of Infectious and Tropical Diseases at Treichville University Teaching Hospital in Abidjan, Côte d’Ivoire. He is a senior lecturer in Medical School of University Felix Houphouet Boigny, in Abidjan, Côte d’Ivoire. He received his medical degree from the university of Abidjan, Côte d’Ivoire and later specialized in infectious and tropical diseases. He was trained in HIV management in France (Marseille and Paris) and has served as a trainer In HIV in several African countries. He is currently the deputy director of the National Agency for Research on AIDS and Hepatitis (ANRS), Research Center of Abidjan, Côte d’Ivoire, the President of the Réseau Africain des Praticiens Assurant la prise en charge des personnes vivant avec le VIH/SIDA (RESAPSI) and is the vice president of Alliance Francophone des Acteurs de la Santé contre le VIH (AFRAVIH). He co-chaired the clinical guidelines developing group of WHO HIV guidelines in 2013 and 2015.He is currently involved in research around HIV therapeutic strategies, HIV and hepatitis co-morbidities, HIV and non- communicable diseases, HIV and ageing and Ebola therapeutic and vaccine trials.

Charles W. Flexner is Professor of Medicine in the Divisions of Clinical Pharmacology and Infectious Diseases, and Professor of Pharmacology and Molecular Sciences in the Johns Hopkins University School of Medicine, USA. He is also Professor of International Health in the Johns Hopkins University Bloomberg School of Public Health. Dr. Flexner is an expert on the basic and clinical pharmacology of drugs for HIV/AIDS and related infections, including viral hepatitis and tuberculosis. His scientific contributions include work on the important roles of pharmacokinetic enhancement, medication adherence, and dosing frequency in the long-term management of HIV/AIDS. He led clinical development teams for seven HIV- related new molecular entities, as well as randomized, prospective trials of once-daily versus twice-daily combination antiretroviral regimens. He has published extensively on anti-infective drug transport and metabolism, and metabolic drug interactions. His current research includes the discovery and development of new molecules and formulations for long-acting parenteral administration for treatment and prevention of HIV infection. He directs the Long Acting/Extended Release Antiretroviral Research Resource Program (LEAP; www.longactinghiv.org) and is Co-Principal Investigator of the Johns Hopkins University Baltimore- Washington-India Clinical Trials Unit (BWI CTU). He currently chairs the AIDS Clinical Trials Group (ACTG) Antiretroviral Treatment Strategies Translational Sciences Group (ARTS TSG), through 2020.

Tendani Gaolathe is a medical doctor and has served as the Principal Investigator (PI) to two cooperative agreements through the Botswana Harvard AIDS Institute Partnership President’s Emergency Program for AIDS Relief (PEPFAR) training and capacity building program. She has over 15 years of experience in capacity building in training, mentoring and supervision of public health initiatives in both the government and private sector. She has experience in the development of training guidelines, manuals and curriculums with content on HIV/AIDS. In addition to the capacity building skills and have significant experience in developing national guidelines in the care and management of HIV/AIDS interventions. She has been the chair of the National HIV/AIDS Treatment guideline Committee since 2007 and has led a team that influenced the national response in changing guidelines for HIV care and management, drug forecasting, budgeting which have resulted in the development and dissemination of national HIV/AIDS treatment guidelines. She has been involved in clinical research, currently serving as Project Director and co-Investigator for the just ending Botswana Combination Prevention Project in conjunction with The Harvard School of Public Health, Ministry of Health and Centers for Disease Control (CDC) which focuses on offering and the implementation of an intervention package that will affect the incidence of HIV at community level. She also serves as country representative for the Botswana –Rutgers global Health Initiative and lectures at the Faculty of Medicine, University of Botswana.

Eric Goemaere is a medical doctor and economist by training. His career with MSF started in 1982, working in Chad and afterwards in several field MSF missions, interrupted by HQ postings to be MSF Brussels medical director (1988 to 1991) and MSF Brussels General Director (1994 to 1999). In 1999 Dr. Goemaere migrated to South Africa to pioneer MSF’s first public health ARV programme in Khayelitsha. Since then Eric has occupied numerous positions in running HIV/TBMSF’s projects in South Africa, finally joining SAMU in 2009 where he is currently the HIV/TB Unit Coordinator supporting and Training MSF Brussels HIV/TB projects in the Region .Eric has received an Honoris Causa doctorate from University of Cape Town (UCT) for his work in HIV, as well as being appointed honorary senior lecturer in the School of Public Health and . He is currently associated with several operational research initiatives as well as numerous publications. He is a member of the South African AIDS Council and of the WHO guidelines advisory board.

Diane Havlir is Professor of Medicine and Associate Chair of Clinical Research at the University of California, San Francisco and Chief of HIV, Infectious Diseases and Global Medicine at San Francisco General Hospital. She was a physician in training when the AIDS epidemic emerged in the 1980s and has cared for HIV- infected patients ever since. She has conducted clinical research in HIV and co-infections for over 25 years, with over 300 publications. Her research focus areas include studies of antiretrovirals, HIV and co infections (TB and malaria) and community-based interventions. She is currently leading several trials focusing on strategies to optimize implementation of ART and TB prevention. Her group is conducting a large community randomized study in East Africa measuring the health, economic and education effects of testing and treating using a patient-centered, streamlined care model. She led the HIV/TB working group of the WHO, served as chair of the WHO HIV Drug Resistance Surveillance Program and has participated on the WHO Guideline Committee since its inception.

John Kinuthia is an Obstetrician Gynecologist, Head of Research and Programs at Kenyatta National Hospital and an honorary lecturer, at the University of Nairobi Institute of Tropical and Infectious Diseases and the Department of and Gynecology. Dr. Kinuthia’s research has focused on evaluation of uptake and utilization of Prevention of Mother-to-Child Transmission (PMTCT) interventions, understanding incidence and cofactors of HIV incidence during pregnancy and after delivery, HIV prevention interventions including use of pre-exposure prophylaxis (PrEP) during pregnancy and breastfeeding. Dr Kinuthia received his undergraduate and postgraduate training at the University of Nairobi. He received a Master’s in Public Health at the University of Washington. He is currently the site Principal Investigator of a study evaluating strategies to optimize adherence and efficacy of PMTCT/ART and evaluation of strategies to deliver PrEP during pregnancy. He is a member of PMTCT and PREP Technical Working Groups coordinated by NASCOP Kenya.

Volodymyr Kurpita is the Director General of Public Health Centre of the Ministry of Health of Ukraine. After obtaining medical degree in Nizhniy Novgorod Medical Institute, Dr Kurpita completed his clinical internship in infection diseases (ID) at the Ukrainian Military Medicine Academy. In 1996 – 2005 Dr Kurpita served as ID specialist to the Ministry of Defense of Ukraine. In 2000-2004 he carried out his research projects focused on Hepatitis B epidemiology and prevention at the Gromashevsky Institute of Epidemiology and ID and was awarded PhD degree. In 2005-2008 he joined the STI/HIV/AIDS Program at the WHO Country Office in Ukraine. In 2008 - 2017 Dr Kurpita served as CEO to All Ukrainian Network of PLWH, Ukrainian NGO running many Public Health projects in Ukraine with financial support from the GFATM, CDC, USAID, EC, other bilateral donors. In 2014-2015 Dr. Kurpita coordinated the Strategic Advisory Group on establishing the National Health Reform Strategy 2015-2020. Dr. Kurpita provides numerous consultancy to WHO, UNAIDS, UNICEF, USAID in Ukraine and across EECA region in the areas of HIV, TB, Hepatitis, Health System Strengthening, and addressing social inequalities. In 2018 he was elected to the position of Director General of the Public Health Centre of the Ministry of Health of Ukraine.

Nagalineswaran Kumarasamy is the Director and Chief of VHS-Infectious Diseases Medical Centre, where he oversees the clinic which provides medical care for more than 20,000 people living with HIV in Chennai, Southern India. Dr. Kumarasamy is the Director and Site Leader for the Chennai Antiviral Research and Treatment (CART) Clinical Research Site of US National Institutes of Health which conducts multisite Therapeutics (ACTG) and prevention(HPTN) clinical Trials. He is the Chennai site Principal Investigator for ACTG, HPTN and START Clinical trials. He is involved as Clinical Investigator for several on-going clinical research projects with University of California-San Diego and Brown University, USA. Dr. Kumarasamy is a clinician and a researcher in Infectious disease with more than 20 years of experience in the field of Medicine and has published more than 375 manuscripts in peer reviewed medical journals. His publications on Impact of Antiretroviral therapy has led to several Antiretroviral scale-up programs in developing countries. Dr. Kumarasamy is an expert panel member for WHO-ARV Treatment guidelines committee since 2003 and a Clinical advisor to Clinton Health Access Initiative. He has an interest on the long-term impact of Antiretroviral Therapy in resource limited settings.

Thuy Le is an HIV researcher at Oxford University Clinical Research Unit Ho Chi Minh City, Viet Nam. Dr Thuy Le trained in at Tufts in Boston and Infectious Diseases at Yale in New Haven, USA. She completed a fellowship in Emerging Infectious Diseases Laboratory at the CDC, completed the Fogarty International Clinical Research Fellowship at the NIH, and obtained a DPhil in epidemiology at the University of Oxford, UK. Currently she is the Deputy Head of the Central Nervous System and HIV Infection Group at the Welcome Trust Major Overseas Program, the Oxford University Clinical Research Unit in Vietnam. She leads a research program focusing on reducing disease burden and improving the diagnosis and treatment of HIV-associated Talaromyces marneffei infection, a leading cause of death inpatients with advanced HIV infection in Asia. She has led the first randomized controlled trial in talaromycosis that provides the definitive evidence that induction therapy with amphotericin B is superior to itraconazole in six-month mortality and calls for amphotericin to be made widely available in Asia. She is a Member of the Scientific Committee of the Asia Pacific AIDS and Co-infection Conference and has published in the Lancet, New England Journal of Medicine, Clinical Infectious Diseases, AIDS, Antiviral Therapy, and Medicine.

Valériane Leroy, Research Director at Inserm U1027, University of Toulouse. She has an MD and degrees in Epidemiology and Public Health specialized in maternal and child health in low income countries. She was appointed full-time research at the Inserm in 1999 working on the prevention of mother-to-child transmission in Africa. Since 2005, she has oriented her research area interests on fighting pediatric infectious disease, mainly HIV in West Africa. Since 2006, she coordinates the Pediatric West African IeDEA (International Epidemiologic Databases to Evaluate AIDS) Cohort NIH-funded, studying health outcomes for HIV-exposed children, and HIV-infected children and adolescents. From 2010-2015, she was Principal Investigator of the MONOD ANRS 12206randomized clinical trial aimed to simplify the LPV- based therapy in children virologically suppressed in Burkina Faso, and Ivory Coast (ClinicalTrial.gov registry number: NCT01127204). Since 2015, she coordinates the DEPISTNEO project assessing maternal HIV and HBV screening at delivery in Abidjan.

Maggie Little is Senior Research Scholar at the Kennedy Institute of Ethics, and Professor of Philosophy at Georgetown. Her research interests include issues in reproduction, clinical research ethics, data ethics, and the structure of moral theory. A Rhodes Scholar and fellow of the Hastings Center, she has twice served as Visiting Scholar in residence at the National Institutes of Health Department of Bioethics and was appointed to the Ethics Committee of the American College of Obstetrics and Gynecology. She is co-founder of The Second Wave Initiative, which works to promote responsible research into the health needs of pregnant women. In her previous role as Director of the Kennedy Institute, Dr. Little oversaw a time of transformative development, including the launch of the world's first Introduction to Bioethics MOOC in April 2014; the inauguration of Conversations in Bioethics, an annual campus-wide event focused on a critical issue in bioethics; the deployment of a series of experimental undergraduate courses utilizing project-based learning and design studio methods. Dr. Little is founder and Director of EthicsLab, a unique team of Philosophers and Designers at Georgetown University that develops new methods to help people build ethical frameworks to better address real-world problems. Ethics Lab works to help surface the moral values at stake in emerging, complex issues, including data ethics and AI, to help build responsible progress.

Imelda Chipo Mahaka is the Country Director, Pangaea Zimbabwe AIDS Trust, Harare, Zimbabwe. Imelda is the Country Director for Pangaea Zimbabwe AIDS Trust and has been involved in policy advocacy around HIV treatment optimization and scale up including access to diagnostic and monitoring and community engagement. Formerly with the UZ-CHS Research Programme and Zimbabwe AIDS Prevention Project, Imelda has extensive experience in HIV/AIDS, SRH behavioral research, using quantitative and qualitative methods, especially working with adolescents. Imelda is a certified Social Worker, project manager and researcher; with a passion for working with and contributing to improved health outcomes for adolescents, women and other priority population groups. She is a member of AfroCAB and CHAI-UNITAID Optimal ARV Project Community Advisory Board, working towards empowered communities.

Othoman Mellouk is an orthodontist by profession, currently leads ITPC’s works on overcoming intellectual property-related barriers to access to . Before joining ITPC, he actively engaged as HIV activist in Morocco, where he participated in the development of the first prevention program targeting men having sex with men in MENA and advocated successfully in the generalization of free access to HIV treatment. From 2002to 2010 he was the chair of the Marrakech city branch of Association de lutte contre lesida (ALCS) and oversaw international relations of ALCS. He is one of the most active advocates for access to medicines in the MENA region with a focus on questions related to intellectual property rights and their effect on access to treatment. He has published several articles and reports about access to medicines in Morocco and the MENA region and has been involved in research on monitoring access to treatment services with the Treatment Monitoring and Advocacy Project of ITPC.

Jacqueline Wambui Mwangi is the Program Officer in Advocacy and Communications at NEPHA. Jacqueline’s education background is in HIV counseling and training. She is an HIV positive activist who has a special interest in the rights of HIV positive persons and advocating for these rights. She has more than ten years’ experience actively working in HIV and SRHR programs in Kenya with work experience that has seen her take lead in various advocacy campaigns that affect PLHIV’ s in Kenya and globally. She currently sits on the African Treatment Community Advisory Board- AFROCAB; representing Kenya as an alternate. Jacque is also a member of the Global Community Advisory Group- GCAG; for the ECHO Trial. Her dream is to see an HIV free-generation.

Wame Mosime is Director of Global Programs and Advocacy at ITPC, based in Botswana. She currently manages all of ITPC’s programmatic and strategic pillars - #TreatPeopleRight #WatchWatchMatters #MakeMedicinesAfforable – across global regions (i.e. Latin America and Caribbean, Eastern Europe and Central Asia, Middle East and North Africa, East Africa, West Africa, and Asia). Ms. Mosime has worked within the civil society and development partner sectors for the over 18 years and has a wide range of expertise includes resource mobilization, policy development, advocacy, community dialogue, community and health systems strengthening, costing analysis and developing innovative practices that engage non-conventional partners in the HIV-response.

Lloyd B. Mulenga is associate professor of Infectious Diseases and Consultant Physician, practicing at the University Teaching Hospital, in Lusaka, Zambia. He is the Chief of the Division of Infectious Diseases at the University Teaching Hospital and the University of Zambia, School of Medicine and Director of the Adult Infectious Diseases Center (AIDC). He the National Coordinator of the Zambia HIV Program for the Ministry of Health. He is also faculty of the Vanderbilt University Medical Center (VUMC), Department of Medicine, Division of Infectious Diseases, Nashville, Tennessee, USA. His research focuses on 1) HIV and clinical outcomes 2) HIV drug resistance and 3) HIV and non-communicable diseases (kidney, cardiovascular diseases and diabetes) and has authored several publications in peer reviewed journals on the same subjects. He is the principle investigator for the Virological Impact of Switching from Efavirenz and Nevirapine based first line ART Regimens to Dolutegravir (VISEND) study - a randomised clinical trial evaluating virologic outcomes among patients switching with detectable and undetectable viral loads from a first-line 2 NRTI + NNRTI-based to 2 NRTI + INSTI-based (DTG) regimens in Zambia and Zimbabwe.

Irene Mukui is the deputy head National AIDS & STI Control Programme, Ministry of Health Kenya and currently coordinates the national roll out of Pre-exposure prophylaxis for HIV. She previously served as the HIV care and treatment lead for over 8 years where she oversaw rapid scale up of ART among PLHIV and introduction of test and treat guidelines. She has previously been involved in development of WHO ARV guidelines as a GDG member in 2013 and 2015 and co-chaired the WHO GDG for “Guidelines on the public health response to pre-treatment HIV drug resistance” 2017.She is a member of the WHO Child Survival Working Group and a co-chair of the WHO HIV Drug resistance steering group. She is involved in a wide range of research on HIV treatment including drug resistance, prevention and implementation science.

Angela Mushavi is the National PMTCT and Pediatric HIV Care and Treatment Coordinator in the Ministry of Health and Child Care, providing technical leadership and guidance for the expansion of PMTCT and Paediatric HIV and AIDS care and treatment programs in Zimbabwe. She is involved in policy formulation and guideline development both at national and international levels. Dr Angela Mushavi has previously provided technical expertise to the WHO HIV guidelines development process since 2010; in 2010 as an external reviewer to the PMTCT guidelines, and in subsequent WHO guideline revisions as a member of the WHO Guideline Development Group and as a member of the technical experts reviewing infant HIV testing and prophylaxis recommendations. Dr Angela Mushavi leads the work on elimination of mother to child transmission of HIV in Zimbabwe and is a member of the WHO Global Validation Advisory Committee (GVAC) that supports global efforts by countries to be recognized as having attained criteria for validation of dual elimination of mother to child transmission of HIV and syphilis. Prior to joining the MOHCC in 2010, Dr Angela Mushavi worked with CDC Namibia as a PMTCT Technical Advisor to the Namibian Ministry of Health and Social Services; and managed a large paediatric ART clinic in Windhoek, providing care and treatment to HIV exposed and HIV positive children and adolescents. A strong advocate for the care of children affected by HIV and AIDS, Dr Angela Mushavi sits on the Steering committee of the African Network for the Care of Children Affected by HIV (ANECCA).

Landon Myer is Head of the School of Public Health & Family Medicine at the University of Cape Town, South Africa, where he is also a Professor in the Division of Epidemiology & Biostatistics. He has a background in anthropology, clinical medicine and epidemiology. His research centres around women's, maternal and child health in the context of HIV/AIDS, and includes clinical and health systems studies, with a particular interest in the health of HIV-infected women receiving ART during pregnancy and the health and development of their children. He has been involved previously in WHO guidelines related to antiretroviral therapy as well as hormonal contraception.

Nicaise Ndembi is the Director of Laboratory Research at the Institute of Human Nigeria (IHV- Nigeria); Adjunct Associate Professor, Division of Epidemiology and Prevention at the IHV, University of Maryland School of Medicine, US and Research Professor, Global Affairs Section, Kanazawa University, Japan. Before that, Dr. Ndembi was head of the Virology Laboratory at the Uganda Virus Research Institute (MRC/UVRI and LSHTM Uganda Research Unit) where he supported several multi-country randomized controlled trials on HIV treatment strategy including the US Centers for Disease Control and Prevention (CDC) cluster-randomized trial to compare the effectiveness of home-based compared with facility-based delivery of antiretroviral therapy (Lancet 2009) and the UK Medical Research Council DART trial (Lancet 2010). Dr. Ndembi has served on several scientific advisory panels and continues to serve as an advisor on HIV drug resistance and control policy to Nigeria’s Federal Ministry of Health. He is a member of the PharmAccess Technical Advisory board for the Pan-African Study for Evaluation of Resistance (PASER) in Africa (Lancet Infectious Diseases 2012). Dr. Ndembi is a graduate of Kanazawa University School of Medicine, Department of Viral Infection and International Health. He has co- authored more than 110 publications in peer reviewed journals and is recipient of numerous Awards. Dr. Ndembi main research interest includes HIV vaccine research especially understanding protective immune responses, genomics epidemiology, microbiome, HFV, HIV diversity and resistance to ARVs.

Sabin Nsanzimana is a physician and epidemiologist. He studied medicine and holds a Master’s Degree in clinical Epidemiology from the University of Rwanda and Doctor of Philosophy in Epidemiology from University of Basel, Switzerland. Currently he serves as the Director of National HIV Program for Rwanda and Division Manager for HIV/AIDS &Viral Hepatitis at the Institute of HIV Disease Prevention and Control, Rwanda Biomedical Centre. For the last 12 years, Dr Sabin has worked for national HIV program, with a senior-level experience in HIV program design, strategic planning, implementation, operational research with focus on global care and treatment of people living with HIV. Dr Sabin served as Principal Investigator for several large research projects including clinical trials in Rwanda and multi-country research collaboration. He recently studied analytically HIV diagnosis, linkage, retention and multidrug experienced patients in entire Rwanda national HIV program for over 2 decades. He has served on several HIV guidelines development group panels of the World Health Organization. He is a peer reviewer for scientific journals and has published extensively on HIV, STI, TB, Viral Hepatitis and cancer in Rwanda and globally. Dr Sabin is a fellow at the African Scientific Institute (ASI) and serves as a lecturer at the University of Global Health Equity in Kigali, Rwanda.

Michael Odo is the Technical Advisor for the HIV Care and Treatment program with the University of Washington (I-TECH) seconded to the Department of HIV/AIDS, Ministry of Health, Malawi. Michael received his medical degree from the University of Calabar and a Master of Public Health degree from the University of Liverpool, UK. He is an experienced multi-country HIV Physician with 23years impactful practice in health systems strengthening and service delivery, and over 14years core progressive management experience in needs assessment, program development, implementation and evaluation of HIV/AIDS services. A former lecturer in the college of medical sciences, University of Calabar, Nigeria, He has been in the lead in national HIV treatment guideline and training curriculum development, as well as a master trainer across countries. Michael was among the team that implemented the $450 million PEPFAR high impact Global HIV/AIDS Initiative Nigeria and the $350 million follow-on strengthening Integrated Delivery of HIV/AIDS Services, both reputed as the largest single PEPFAR investment in a single country. He is an active member of international learning networks, including the ICAP-supported HIV Coverage, Quality and Impact Network (CQUIN) and a past and current Investigator of several HIV/AIDS related implementation research.

Filipe de Barros Perini is an infectious disease specialist and the head of the treatment and care team at the Department of STIs, HIV/AIDS and Viral Hepatitis, Ministry of Health, Brazil. Dr. Perini received his medical degree from Federal University of Paraná, Brazil and made his medical residency in infectious diseases at Emilio Ribas Infectious Diseases Institute – São Paulo, Brazil. He is also a specialist in Management of Networks from Oswaldo Cruz Foundation (FioCruz) – Rio de Janeiro and is currently studying for a Master's degree in Public Health Policies at Owsvaldo Cruz Foundation (FioCruz) - Brasília, Brazil. Dr. Perini worked as a medical doctor, trainer and HIV/STI program manager in South of Brazil in several STI, HIV and hepatitis projects, especially in HIV shared care (task shifting) among specialized and primary care health services. Since 2017, is the head of Care and Treatment team of the Department of STIs, HIV/AIDS and Viral Hepatitis, MoH, Brazil, responsible for organizing and update the Brazilian Clinical Guidelines on care and treatment for PLWH, and for the implementation of new treatment recommendations and biomedical prevention strategies for HIV care, in Brazil.

Anton Pozniak is a Consultant Physician at the Chelsea and Westminster Hospital NHS Foundation Trust and Honorary Professor at the London School of Tropical Medicine and Hygiene London UK. Anton Pozniak studied medicine at the University of Bristol UK and qualified in 1979. He started caring for patients with HIV in 1983 at the Middlesex Hospital, London UK. He went to Zimbabwe as a Consultant Physician in 1989 where he researched for his doctorate in TB/HIV and then moved back to the UK in 1991. He ran the HIV research unit at King’s College, London before moving to his current position as Consultant Physician at the Chelsea and Westminster Hospital in 1998. He became a fellow of the Royal College of Physicians in 1996. He has been made a Life member of the British HIV Association and has helped write the British HIV Association (BHIVA) anti-viral HIV guidelines and chairs the TB/HIV guidelines committee. He was an advisor on HIV and AIDS to the UK Government Health Select Committee and the Expert advisory group on AIDS for the UK Department of Health. He is a DSMB chair for several MRC and PENTA studies. He is President of the International AIDS Society and a Governing Board member of the European AIDS Clinical Society. He is President of the European AIDS trial network NEAT-ID. He is on the board of the Charity CUAMM UK. He is Principal Investigator for a Test and Treat project in Tanzania. He has published widely on clinical aspects of HIV treatment and care and HIV tuberculosis.

Opass Putcharoen is the director of Emerging Infectious Diseases Clinical Center, Thai Red Cross and a senior lecturer of the division of infectious diseases, Department of Medicine, King Chulalongkorn Memorial Hospital, Chulalongkorn University, Bangkok, Thailand. Dr. Opass Putcharoen is also an assistant professor at the faculty of medicine, Chulalongkorn University. In 1998, Dr. Opass received a medical degree from Kon Kean University, Thailand and then completed his residency and fellowship (infectious diseases) training at Chulalongkorn University. During 2008-2010, he received training grants from the Fogarty International Center at NIH, USA. In 2008-2011, he was a research fellow in HIV drug resistance at the department of and infectious diseases, Harvard School of Public and postdoctoral fellow at the section of retroviral therapeutics, division of infectious diseases, Brigham and Women’s Hospital, Harvard School of Medicine, Boston, MA, USA. His current researches are focusing on long-term complications of antiretroviral therapy, HIV drug resistance and co-infections in resource- limited settings. He has provided educational supports and training for HIV physicians from Malaysia, Myanmar, and Laos. Dr. Putcharoen is currently executive secretary of the panel members for the development of Thai ARV guidelines and scientific member of Thai STI guidelines.

Kenly Sikwese is the Executive Director at Afrocab Treatment Access Partnership. He served as inaugural Steering Committee member of the Robert Carr Fund, African NGOs board member at the UNAIDS PCB and similar capacity and various other organizations. Kenly served as a Co-Chair of the UNAIDS 90-90-90 target setting advisory group and the 90-90-90 Scientific Technical Advisory Committee (STAC) until 2018. He served at the Network of Zambian People Living with HIV and supported ten national networks of PLHIV to implement the PLHIV Stigma Index between 2009-2013. He has served as WHO Guidelines Group member in 2010; 2013, 2015, and 2017. Kenly actively participates in global and regional treatment access initiatives as a community advocate, primarily focusing on optimizing HIV treatment and prevention mechanisms in Africa. He currently serves as a member of the Unitaid Board.

Katayoun Tayeri is infectious diseases specialist, HIV/AIDS fellowship and national HIV/AIDS care and treatment consultant. She has been involved in HIV prevention, diagnosis and care for general population and key population (with a special focus on IV drug users) in national and provincial level, for over 17 years. She is one of members of national scientific HIV/AIDS care and treatment committee and closely involved in developing and revising national HIV guidelines. She has been organized and conducted high level workshops in field of HIV/AIDS care and treatment for general physicians (GPs) and infectious diseases specialists (IDs), 231 GPs who are working in VCT clinics and 64 IDs who are the provincial HIV focal points have been trained. She has organized and managed two virtual networks of “AIDS physicians” and “HIV focal points. Involvement in developing national HIV/AIDS care and treatment guidelines, developing especial guideline for HIV chronic care, guideline for reducing loss to follow up among PLWH, guideline of integration HIV testing services (HTS) in harm reduction centers, training manuals about PMTCT and Adherence to treatment for PLWH and health care providers, HIV nutritional guidelines for PLWH and care providers are some of her activities and publication. She also developed management information system (MIS) for national HIV program that led to improve quality of data documentation and management. In 2016 she successfully coordinated the expansion of using new HIV testing approach (WHO HIV testing algorithm) throughout the country. She has been involved in integration of HTS in harm reduction centers throughout the country, conducted pilot study of ART delivery in DIC and MMT clinics and HIV primary and acquired resistance research.

Anna Turkova is a Senior Clinical Research Fellow at the MRC CTU at UCL, London, and an Honorary Consultant, Infectious Diseases, at the Great Ormond Street Hospital, London. She graduated in Russia and has been working in the UK since 2002. Her research activities are focused on HIV, TB, HCV and co- infections. Dr Turkova is a trial clinician in several large international pediatric HIV and TB randomized controlled trials run by MRC CTU at UCL. She coordinates epidemiological and observational collaborative studies in Eastern Europe. At Great Ormond Street Hospital, as part of Infectious Diseases team, she manages children and families affected by HIV, viral hepatitis and TB. Dr Turkova is a member of WHO-led Pediatric Drug Optimization and Pediatric Antiretroviral Working groups. She is a member of Pediatric European Network for Treating AIDS and other Infectious Diseases (PENTA-ID) steering committee. She co-chaired the clinical guidelines developing group of PENTA HIV treatment guidelines in 2015 and was part of the writing group of the 2016 edition. Dr Turkova facilitates on-line and residential PENTA HIV and TB training courses in western and eastern Europe and Africa and teaches on MSc in in Clinical Trials at the MRC CTU at UCL.

Francois Venter heads Ezintsha, a sub-syndicate of the Wits Reproductive Health and HIV Institute at the University of the Witwatersrand, Johannesburg. He leads multiple antiretroviral treatment optimization studies and has an active interest in public sector access to HIV services. He is currently working on new first and second line antiretroviral options, patient linkage to care interventions, and HIV self-testing projects. He has led large PEPFAR-funded HIV programmes in South Africa, including one that focuses on truckers and sex workers. He has been represented on South African and regional HIV guidelines for over a decade, having done almost all his training within South Africa. He is an advisor to the South African government, ACTG, Southern African HIV Clinicians Society, UNAIDS and WHO. He has been involved in several human rights cases involving HIV within the Southern African region and has an active interest in medical ethics. His major research currently focusses on combinations of newer drugs to improve the resistance and potency while lowering the cost of first and second line antiretrovirals, improve early diagnosis of HIV, facilitate access to pre-exposure prophylaxis, as well as using patient information to drive improved linkage to care after diagnosis. He supervises multiple local and international Masters and PhD students, and is the convener of the regional Diploma in HIV Medicine and Diploma in Sexual Health and HIV for the Southern African Colleges of Medicine.

Evgeny Voronin is a medical doctor and currently has two roles: the first in the Russian Federation Ministry of Health as the Chief specialist for HIV-infection and the second in the Republican Hospital of Infectious Diseases as Head Physician. Also, he is a direct report into the Russian Ministry of Health. Evgeny Voronin has been involved in HIV-prevention and HIV-treatment programs for women and children, for over 25 years. He has led initiatives in early diagnosis detection among newborns and early- years. Furthermore Dr. Voronin has played a major part in prevention of mother to child HIV transmission, through his work at the National Center for pregnant women and children with HIV. He is also Professor of the North-West Medical Academy and actively lectured PhD doctors and students for about 20 years. Dr. Voronin organized the first fast-track role out in 'early diagnostics' in Russia. As part of his responsibilities he coordinated the work of all AIDS Centers in the Russian Federation, which significantly reduced the rate of transmission of HIV from mother to child.

Alice Welbourn, researcher, trainer, and global advocacy activist on SRH&R in the context of VAW & HIV. She lived in Africa during most of the 1980s, working on community-based gender- and youth- focused health initiatives. She became a participatory learning approaches trainer in 1990. Diagnosed with HIV in 1992, she then wrote the “Stepping Stones”, training package on gender, generation, HIV, communication and relationship skills (updated 2016). Alice was Chair of the International Community of Women Living with HIV/AIDS (ICW) from 2002-5. In 2008, she founded the Salamander Trust. Salamander’s work with partners includes: a) a Global Values and Preferences Survey, on the SRHR of women living with HIV, which informed the WHO 2017 Guideline on this topic; b) a global treatment access review for UN Women which highlights high levels of intimate partner and health-center violence experienced post-diagnosis; developed c) for UNAIDS the ALIV[H]E framework, to enable meaningful community involvement in research and implementation of effective and ethical initiatives to address VAWG and HIV at community level.

Annemarie Wensing is a virologist at the University Medical Center at Utrecht, the Netherlands. She worked at the HIV outpatient clinic in Utrecht from 1998 to 2002 and was subsequently trained as a clinical virologist. She advises infectious disease specialist from multiple HIV centers. She teaches at the Utetcht Medical and Pharmacy School. She published over a hundred specific papers. Her research focuses on HIV drug resistance, transmission, eradication and reservoirs. She is co-PI of EPISTEM, investigating potential HIV cure via SCT. She is a founding member of ESAR, and the SPREAD program, regional representative for EAC, member of the WHO HIV Drug Resistance Expert Panel, and Chair of the IAS-USA mutations panel.